Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study

Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study

Christoph Losem,1 Michael Koenigsmann,2 Christine Rudolph3 1Praxis für Hämatologie und Onkologie, Neuss, 2Onkologisches Ambulanzzentrum, Marienstr, Hannover, 3Hospira Germany, A Pfizer Company, München, Germany Background: Symptomatic anemia is a frequent and severe comp...

Full description

Bibliographic Details
Main Authors: Losem C, Koenigsmann M, Rudolph C
Format: Article
Language:English
Published: Dove Medical Press 2017-02-01
Series:OncoTargets and Therapy
Subjects:
Epoetin
erythropoiesis-stimulating agents
anemia
chemotherapy
biosimilar epoetin zeta
Online Access:https://www.dovepress.com/biosimilar-retacritr-epoetin-zeta-in-the-treatment-of-chemotherapy-i-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/biosimilar-retacritr-epoetin-zeta-in-the-treatment-of-chemotherapy-i-peer-reviewed-article-OTT

Similar Items